Erdosteine

DRUG5 trials

Sponsors

Adams Respiratory Therapeutics, Edmond Pharma, Hull University Teaching Hospitals NHS Trust, Tanta University, Pierachille Santus, MD, PhD

Conditions

COPDChronic BronchitisChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)Fatty Liver

Phase 1

Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease

RecruitingNCT07242222

Tanta UniversityFatty Liver

Start: 2025-11-20End: 2026-11-20Target: 50Updated: 2025-12-10

Phase 2

Phase 2 Study - Erdosteine in Patients With CB/COPD

CompletedNCT00338507

Adams Respiratory TherapeuticsChronic Bronchitis, Chronic Obstructive Pulmonary Disease

Start: 2006-03-31Target: 400Updated: 2007-12-06

Phase 3

The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)

Edmond PharmaChronic Obstructive Pulmonary Disease (COPD)

Start: 2009-08-31End: 2015-09-30Target: 492Updated: 2014-06-13

Phase 4

Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

WithdrawnNCT01176318

Hull University Teaching Hospitals NHS TrustChronic Obstructive Pulmonary Disease

Start: 2010-08-10End: 2012-01-13Updated: 2019-06-19

Unknown Phase

Immuno-inflammatory Response of Erdosteine in COPD

Not yet recruitingNCT07329946

Pierachille Santus, MD, PhDCOPD

Start: 2026-09-01End: 2027-12-31Target: 30Updated: 2026-04-29